Cargando…

The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma

Rationale: Glycogen synthase kinase-3β (GSK-3β) plays key roles in metabolism and many cellular processes. It was recently demonstrated that overexpression of GSK-3β can confer tumor growth. However, the expression and function of GSK-3β in hepatocellular carcinoma (HCC) remain largely unexplored. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shuaishuai, Gao, Weiwei, Tang, Juan, Zhang, Huaifang, Zhou, Yuqi, Liu, Jie, Chen, Kun, Liu, Fangzhou, Li, Wengang, To, Sally K. Y., Wong, Alice Sze Tsai, Zhang, Xiao-kun, Zhou, Hu, Zeng, Jin-Zhang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956800/ https://www.ncbi.nlm.nih.gov/pubmed/31938062 http://dx.doi.org/10.7150/thno.38711

Ejemplares similares

Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect
por: Ma, Luyuan, et al.
Publicado: (2020)

Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells
por: Liu, Tianhua, et al.
Publicado: (2017)

Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway
por: Qi, Feng, et al.
Publicado: (2021)

SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway
por: Tang, Xiaohui, et al.
Publicado: (2021)

Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma
por: Li, Ming, et al.
Publicado: (2016)

Antagonist Effect of Triptolide on AKT Activation by Truncated Retinoid X Receptor-alpha
por: Lu, Na, et al.
Publicado: (2012)

Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p
por: Ye, Junfeng, et al.
Publicado: (2019)

Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma
por: Ye, Junfeng, et al.
Publicado: (2018)

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
por: Li, Jun, et al.
Publicado: (2018)

20(S)-protopanaxadiol promotes the migration, proliferation, and differentiation of neural stem cells by targeting GSK-3β in the Wnt/GSK-3β/β-catenin pathway
por: Lin, Kaili, et al.
Publicado: (2020)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

The Ginsenoside Compound K Suppresses Stem-Cell-like Properties and Colorectal Cancer Metastasis by Targeting Hypoxia-Driven Nur77-Akt Feed-Forward Signaling
por: Zhang, Minda, et al.
Publicado: (2022)

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
por: Tang, Weiwei, et al.
Publicado: (2020)

Targeting to the non-genomic activity of retinoic acid receptor-gamma by acacetin in hepatocellular carcinoma
por: Zeng, Wenjun, et al.
Publicado: (2017)

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Ma, Yongfang, et al.
Publicado: (2021)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis
por: Shimizu, Masahito, et al.
Publicado: (2012)

Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma
por: Woo, Hyun Young, et al.
Publicado: (2021)

Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma
por: Giovannini, Catia, et al.
Publicado: (2013)

The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma
por: Wu, Zhixian, et al.
Publicado: (2022)

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
por: Sun, Guangshun, et al.
Publicado: (2022)

Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma
por: Zhang, Xinning, et al.
Publicado: (2022)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization
por: Liu, Lei, et al.
Publicado: (2016)

miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
por: Liu, Kai, et al.
Publicado: (2021)

GSK3β rephosphorylation rescues ALPL deficiency-induced impairment of odontoblastic differentiation of DPSCs
por: Zhang, Liqiang, et al.
Publicado: (2021)

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma
por: Zheng, Min, et al.
Publicado: (2017)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes
por: Xie, Yong, et al.
Publicado: (2021)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
por: Dudgeon, Crissy, et al.
Publicado: (2012)

Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells
por: Wu, Man, et al.
Publicado: (2018)

Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy
por: Liao, Han, et al.
Publicado: (2019)

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
por: Lu, Haofeng, et al.
Publicado: (2022)

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021)

Of Retinoids and Organotins: The Evolution of the Retinoid X Receptor in Metazoa
por: Fonseca, Elza, et al.
Publicado: (2020)

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
por: Zhang, Yafei, et al.
Publicado: (2012)

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
por: Lu, Shuai, et al.
Publicado: (2018)

Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
por: Liu, Qingjun, et al.
Publicado: (2011)

Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Zhang, Xia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7p74p9nv1807a4r14mcrcppl8n